Cardiovascular And Metabolic Disorders
Researchers assessed whether current metabolic parameters are inversely associated with cognitive functioning.
Patients with remitted bipolar disorder and emotional hyper-reactivity also have significantly higher levels of low-grade inflammation, hypertension, and impaired glucose metabolism, indicating a higher risk for cardiometabolic dysfunction.
The United States Preventive Services Task Force does not recommend screening with resting or exercise electrocardiography in asymptomatic individuals at low risk for cardiovascular disease events.
The 1-year cardiovascular mortality hazard ratio (HR) for alendronate users was 0.33 (95% CI, 0.17 to 0.65) and 0.55 for incident myocardial infarction (95% CI, 0.34 to 0.89).
Researchers investigated effects of eplerenone on insulin sensitivity, inflammatory indices, and other metabolic parameters in HIV.
Younger patients treated with antipsychotics after experiencing a first episode of psychosis are at an increased risk for metabolic syndrome and cardiovascular disease.
Researchers used multiparametric cardiovascular magnetic resonance imaging to examine the correlation between aortic stiffness and LV geometry in younger adults with type 2 diabetes.
Knowing that certain characteristics increase the risk for dermatology patients who may have metabolic syndrome will enable clinicians to identify patients who may have specific cardiovascular risks.
In patients with asymptomatic left ventricular systolic dysfunction, diabetes is associated with an increased risk of developing heart failure.
The frequency of metabolic syndrome among patients with SLE was approximately 45%.
Using both public and private health insurance claims data, investigators conducted a retrospective cohort study to assess cardiovascular risk in the setting of diabetes and rheumatoid arthritis.
Physically active young adults with type 1 diabetes have alterations in mitochondrial ultrastructure and bioenergetics within skeletal muscle.
Findings highlight the importance of screening for metabolic syndrome (MS) and the potential for MS to influence alanine aminotransferase and its interpretation in the context of HBV treatment decisions.
Compared with the enalapril-treated group, those treated with sacubitril/valsartan were found to have significantly slower kidney decline.
In patients with type 2 diabetes and with relatively preserved estimated glomerular filtration rate, reduced levels of soluble Klotho predict renal function decline independent of traditional risk markers.
Researchers designed a cohort study to examine whether serum thyroid hormone levels within the reference range are predictive factors for developing metabolic syndrome in adults.
The renal protective benefit was seen in patients with both reduced (eGFR <60mL/min/1.73m2) and preserved (eGFR ≥60mL/min/1.73m2) renal function.
Researchers examined whether menopausal symptoms, quality of life, and depression are related to arterial stiffness, a risk factor for cardiovascular disease.
Changes in serum insulin and homeostatic model assessment of insulin resistance and beta cell function were significantly greater compared to the control diet
Compared with standard care, noninvasive coronary artery disease screening reduced cardiac events by 27% in individuals with asymptomatic diabetes. Results justify larger, appropriately powered trials to potentially revisit current recommendations.
Results from the ongoing Platinum Study revealed the prevalence of risk factors for CVD among survivors of testicular cancer who received chemotherapy for their cancer.
Only about 50% of adults with familial hypercholesterolemia are on statin therapy, and approximately 30% of those are taking high-intensity statins.
Change in body mass index to overweight during puberty significantly increases men's risk of heart failure later in life.
Although various clinical and psychosocial factors were associated with unhealthy lifestyle factors and higher risk for CVD, the strongest associations were with negative symptoms.
A recent study evaluated the effects of SGLT-2i and other glucose-lowering drugs on cardiovascular event outcomes in patients with type 2 diabetes from 6 countries in 3 world regions.
The new analysis focuses on the remaining 4960 patients, who had prediabetes at the start of the trial.
Researchers examined the effect of menopausal hormone therapy on left ventricular and left atrial chamber structure and function changes, which are markers of subclinical cardiovascular disease.
The Tresiba label was updated to reflect safety outcomes from the DEVOTE trial.
Statin-associated muscle pain can hinder medication adherence which could potentially lead to an increased risk of cardiovascular events.
Researchers conducted a prospective, population-based cohort study to assess the risk for cardiovascular disease in postmenopausal women with increased androgen levels.
Endocrinology Advisor Articles
- Subclinical Hypothyroidism: Controversies in Testing and Treatment
- Favorable Outcomes With Second-Generation Insulin Analogs in Type 2 Diabetes
- Fatigue Management Contributes to Effective Endometriosis Care
- Assessment of Low-Dose Aspirin As Chemoprevention in Type 2 Diabetes
- Treatment With Alemtuzumab May Frequently Induce Thyroid Dysfunction
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Adjunctive Aripiprazole Lowers Prolactin Levels in Women With Psychosis
- When Physicians Become Patients: Challenges in Seeking Health Care
- Statin Use and Cardiovascular Risk Perception Varies Among Races
- Impact of a Longer Work Week on Diabetes Incidence
- Relationship Between Estradiol Level and Mortality in Elderly Men